Former Amorfix Board member Walter Von Wartburg to act as Board advisor
TSX: AMF
TORONTO, March 20, 2014 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that former board member Dr. Walter von Wartburg will re-join the Company as a senior advisor to the Board of Directors.
"Dr. von Wartburg served as a Board member for several years and we are very pleased that Amorfix will continue to benefit from his wealth of pharmaceutical industry and business experience" said Amorfix President and CEO, Dr. Robert Gundel.
Dr. von Wartburg has held senior management positions within the global pharmaceutical industry including Roche, Ciba-Geigy and Novartis for over 20 years, specializing in US/EU regulatory affairs for drug and medical devices. He was a professor of public health policy at the Saint Gall Graduate School of Economics, Business and Public Administration, a law graduate of the Universities of Basel, Paris, Princeton, Stanford and Harvard Law School. He has published books and articles on subjects ranging from drug legislation, social acceptance of gene technology, to issues management and business administration. Dr. von Wartburg is currently Partner in a private law practice. Dr von Wartburg served on the Amorfix Board of Directors from October 2010 until his retirement in January 2014.
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for both Alzheimer's disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Amorfix Life Sciences Ltd.
For further information:
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
[email protected]
Warren Whitehead
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 644-7358
Fax: (416) 847-6899
[email protected]
Share this article